Abstract
Advances in virology of the hepatitis C virus (HCV) have enabled rapid progress in developing direct-acting antivirals (DAAs) that directly target viral proteins. The use of these drugs has considerably improved treatment outcomes. However, the effects of these inhibitors are weakened by the presence of resistance-associated variants (RAVs). In addition, it is becoming clear that DAA-resistant variants exist in a certain proportion of cases that are naïve to DAAs. Genotype 1b variants that are resistant to NS3 protease inhibitors exist naturally, although they are uncommon. Variants resistant to nucleotide NS5B inhibitors are almost never observed in treatment-naïve patients. Conversely, the genotype 1b NS5A Y93H variant and the genotype 1a NS3 Q80K variant, which are resistant to NS5A or NS3/4 inhibitors, respectively, reportedly exist at relatively high frequency; hence, more care needs to be taken when administering DAA treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–46.
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.
Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–3.
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.
Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645–53.
Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352–4.
Itakura J, Kurosaki M, Takada H, Nakakuki N, Matsuda S, Gondou K, Asano Y, et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to IL28B genotype and are sensitive to interferon-based therapy. Hepatol Res. 2015;45(10):E115–21.
Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J, Wyckmans Y, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–6.
Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360–7.
McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother. 2008;52:1604–12.
Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–74.
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21:762–8.
Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, et al. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res. 2007;35:D363–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Suda, G., Ito, J., Morikawa, K., Ogawa, K., Sakamoto, N. (2017). Incidence and Characteristics of Naturally Occurring Drug-Resistant Hepatitis C Virus Strains. In: Chayama, K. (eds) Hepatitis C Virus Treatment. Springer, Singapore. https://doi.org/10.1007/978-981-10-2416-0_6
Download citation
DOI: https://doi.org/10.1007/978-981-10-2416-0_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-2415-3
Online ISBN: 978-981-10-2416-0
eBook Packages: MedicineMedicine (R0)